The firm said that its shares will begin trading on the OTCQB exchange starting on Feb. 22.
Under the agreement, Precipio would become a wholly owned subsidiary of Transgenomic, which would then adopt the new name Precipio.
JoyingBio will distribute Transgenomic's multiplexed ICE COLD-PCR kits in China and Biotron Healthcare will do the same in India.
The agreement gives Ventana access to results from a collaboration and licensing agreement that Transgenomic made separately with the University of Melbourne.
The firm's labs services revenues were unchanged, but it saw a slight increase in sales mainly from higher oncology revenue and grants.
Two Boston-based researchers shared methods for detecting circulating nucleic acid biomarkers for potential use in cancer diagnosis and monitoring.
The partners will augment the multiplexing capabilities of ICE COLD-PCR, which was developed at Dana-Farber and is exclusively licensed to Transgenomic.
The lower sales from contract laboratory services reflect Transgenomic's continued refocusing on its core ICE-COLD PCR molecular diagnostic technology.
The deal covers four of Transgenomic's liquid biopsy cancer assays, which detect actionable mutations associated with sensitivity or resistance to therapy.
The firm has signed Spectron Scientific and Sowa Trading Company to distribute its ICEme mutation enrichment kit in China and Japan, respectively.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.